# Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

> **NCT00660881** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 210 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Epratuzumab

## Key facts

- **NCT ID:** NCT00660881
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2012-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660881, "Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00660881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*